RATIO-SALBUTAMOL SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

SALBUTAMOL (SALBUTAMOL SULFATE)

থেকে পাওয়া:

TEVA CANADA LIMITED

এটিসি কোড:

R03AC02

INN (আন্তর্জাতিক নাম):

SALBUTAMOL

ডোজ:

1MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

প্রশাসন রুট:

INHALATION

প্যাকেজ ইউনিট:

10ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0108887007; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2018-05-18

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate respirator solution
1 mg/mL
Bronchodilator
(beta
2
-adrenergic stimulant)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Control: 166142
DATE OF PREPARATION:
JULY 24, 2013
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
8
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................................
14
PART II: S